FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312858703> ?p ?o ?g. }

• W4312858703 endingPage "185" @default.
• W4312858703 startingPage "175" @default.
• W4312858703 abstract "Background/Aim: The evidence showed that in the development of diabetes mellitus type 2 (DMT2) and coronary heart disease (CHD) significant role is played by metabolic risk factors: insulin resistance (IR), dyslipidaemia and obesity. Beside metabolic factors, increase in inflammatory markers such as fibrinogen and hs-C reactive protein (hsCRP) plays a role in developing CHD. Metabolic disorders are thought to also be present in patients with impaired glucose tolerance (IGT) and could contribute to development of CHD in these individuals. Aim of this study was to investigate the behaviour of metabolic parameters and chronic inflammation markers in patients with IGT on glucose tolerance test and associated CHD. Methods: The trial included 4 groups of 30 subjects: a) IGT with CHD, b) IGT without CHD, c) CHD without IGT and d) control group without CHD and with normal glucose tolerance (NGT). Within each group glucoregulation parameters were measured (fasting glucose and Hb1Ac). Oral glucose tolerance test (OGTT) with 75 g glucose load was performed and IR parameters calculated (using HOMA-IR, Matsuda index, Quicki index, HOMA1%B), lipid profile was done, waist/hip ratio was measured, as well as fibrinogen and hsCRP. CHD diagnosis was determined by typical signs of previous myocardial infarction on ECG, echocardiogram and/or ergometry (Bruce protocol). Results: Subjects with IGT, but no CHD and those with both IGT and CHD had statistically significantly higher triglyceride and cholesterol levels and manifest IR with decreased insulin sensitivity compared to subjects with CHD, but no IGT and control group. Group with both IGT and CHD was found to have significantly higher fibrinogen and hsCRP concentrations. Conclusion: IR and hyperlipidaemia, together with chronic inflammation mediators, are potential predictors of the development of glucose tolerance disorders; hence interventional treatment during IGT period or during hyperinsulinaemia could give patients better opportunity to prevent or postpone onset or development of diabetes and its complications." @default.
• W4312858703 created "2023-01-05" @default.
• W4312858703 creator A5007453259 @default.
• W4312858703 creator A5008421788 @default.
• W4312858703 creator A5019936883 @default.
• W4312858703 creator A5040004229 @default.
• W4312858703 creator A5055286685 @default.
• W4312858703 creator A5059988297 @default.
• W4312858703 date "2022-01-01" @default.
• W4312858703 modified "2023-09-27" @default.
• W4312858703 title "Metabolic disorders in patients with impaired glucose tolerance, with or without underlying ischaemic heart disease" @default.
• W4312858703 cites W1555860740 @default.
• W4312858703 cites W1965006643 @default.
• W4312858703 cites W1969288921 @default.
• W4312858703 cites W1969682145 @default.
• W4312858703 cites W1981384500 @default.
• W4312858703 cites W1983839288 @default.
• W4312858703 cites W1997001621 @default.
• W4312858703 cites W2003106879 @default.
• W4312858703 cites W2011707168 @default.
• W4312858703 cites W2014318859 @default.
• W4312858703 cites W2016432577 @default.
• W4312858703 cites W2018487032 @default.
• W4312858703 cites W2028288347 @default.
• W4312858703 cites W2046117118 @default.
• W4312858703 cites W2050158303 @default.
• W4312858703 cites W2058709767 @default.
• W4312858703 cites W2060449981 @default.
• W4312858703 cites W2089866062 @default.
• W4312858703 cites W2092398617 @default.
• W4312858703 cites W2095068198 @default.
• W4312858703 cites W2099693424 @default.
• W4312858703 cites W2100083473 @default.
• W4312858703 cites W2100310454 @default.
• W4312858703 cites W2101613925 @default.
• W4312858703 cites W2101944785 @default.
• W4312858703 cites W2105362864 @default.
• W4312858703 cites W2105766576 @default.
• W4312858703 cites W2109958590 @default.
• W4312858703 cites W2111806993 @default.
• W4312858703 cites W2114467602 @default.
• W4312858703 cites W2115108568 @default.
• W4312858703 cites W2118072799 @default.
• W4312858703 cites W2125951189 @default.
• W4312858703 cites W2131136365 @default.
• W4312858703 cites W2132279603 @default.
• W4312858703 cites W2133795831 @default.
• W4312858703 cites W2139943527 @default.
• W4312858703 cites W2142972784 @default.
• W4312858703 cites W2150921017 @default.
• W4312858703 cites W2151823333 @default.
• W4312858703 cites W2153712580 @default.
• W4312858703 cites W2155311570 @default.
• W4312858703 cites W2162231109 @default.
• W4312858703 cites W2163092745 @default.
• W4312858703 cites W2165734788 @default.
• W4312858703 cites W2168536185 @default.
• W4312858703 cites W2185461071 @default.
• W4312858703 cites W2192199174 @default.
• W4312858703 cites W2260871114 @default.
• W4312858703 cites W2318881450 @default.
• W4312858703 cites W2732251850 @default.
• W4312858703 cites W2765612509 @default.
• W4312858703 cites W2788303832 @default.
• W4312858703 cites W2954707625 @default.
• W4312858703 cites W3033483381 @default.
• W4312858703 cites W3210445985 @default.
• W4312858703 cites W4210956151 @default.
• W4312858703 cites W4230870013 @default.
• W4312858703 cites W4235479662 @default.
• W4312858703 doi "https://doi.org/10.5937/scriptamed53-36711" @default.
• W4312858703 hasPublicationYear "2022" @default.
• W4312858703 type Work @default.
• W4312858703 citedByCount "0" @default.
• W4312858703 crossrefType "journal-article" @default.
• W4312858703 hasAuthorship W4312858703A5007453259 @default.
• W4312858703 hasAuthorship W4312858703A5008421788 @default.
• W4312858703 hasAuthorship W4312858703A5019936883 @default.
• W4312858703 hasAuthorship W4312858703A5040004229 @default.
• W4312858703 hasAuthorship W4312858703A5055286685 @default.
• W4312858703 hasAuthorship W4312858703A5059988297 @default.
• W4312858703 hasBestOaLocation W43128587031 @default.
• W4312858703 hasConcept C126322002 @default.
• W4312858703 hasConcept C134018914 @default.
• W4312858703 hasConcept C164705383 @default.
• W4312858703 hasConcept C2777391703 @default.
• W4312858703 hasConcept C2778163477 @default.
• W4312858703 hasConcept C2778913445 @default.
• W4312858703 hasConcept C2780578515 @default.
• W4312858703 hasConcept C2780609358 @default.
• W4312858703 hasConcept C2910068830 @default.
• W4312858703 hasConcept C511355011 @default.
• W4312858703 hasConcept C555293320 @default.
• W4312858703 hasConcept C71924100 @default.
• W4312858703 hasConceptScore W4312858703C126322002 @default.
• W4312858703 hasConceptScore W4312858703C134018914 @default.
• W4312858703 hasConceptScore W4312858703C164705383 @default.
• W4312858703 hasConceptScore W4312858703C2777391703 @default.

• next